about
Stimulant dependence and stimulant-associated psychosis: clinical characteristics and age of onset in a native American community sampleMedical use, illicit use, and diversion of abusable prescription drugsReduced behavioral and neural activation in stimulant users to different error rates during decision making.Extra-medical stimulant dependence among recent initiatesConcurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youthsSimilar discriminative-stimulus effects of D-amphetamine in women and men.Misuse of methamphetamine and prescription stimulants among youths and young adults in the community.Doctor shopping for medications used in the treatment of attention deficit hyperactivity disorder: shoppers often pay in cash and cross state lines.The nonmedical use of prescription ADHD medications: results from a national Internet panel.Clinical characteristics of alcohol combined with other substance use disorders in an American Indian community sample.An item response theory modeling of alcohol and marijuana dependences: a National Drug Abuse Treatment Clinical Trials Network study.Heterogeneity of stimulant dependence: a national drug abuse treatment clinical trials network study.Prescription drug abuse among adolescent arrestees: correlates and implications.Health-compromising practices of undergraduate college students: Examining racial/ethnic and gender differences in characteristics of prescription stimulant misuse.Amphetamine treatment affects the extra-hypothalamic vasopressinergic system in a sex- and nucleus-dependent manner.Attitudes Toward Cognitive Enhancement in Users and Nonusers of Stimulants for Cognitive Enhancement: A Pilot Study
P2860
Q34005873-1D443C6D-1319-4163-8E1E-C3D388F7236EQ34502326-11D44484-3FC7-4F7B-8358-AA0706C6FDA4Q34856720-547D5E62-4B72-4196-81C1-45E65AA01741Q35082566-D89F4A9B-B641-461D-865F-436AA4114724Q35090740-91B61136-A211-4C9C-B8F6-CDE9BC5F507AQ36026733-FFBDBF22-8CED-4326-BB8A-F115CA5DAA47Q36116697-70FEDBA5-B05D-45B2-A37F-4A7835BF3D5CQ36357130-DC957405-7AF1-499E-BB1F-A201FE9E96A8Q36398961-B0AC212C-A6D3-4D11-AF6C-70A002D4B547Q36689601-65BE3906-A9EE-493B-B43F-2CFFDE91DFDCQ37162696-2FACD26A-2CAC-4463-9FBD-BB21B7023682Q37348795-D8A7309E-B610-4225-9FA8-A67BADB8AFB8Q39886812-79E89CC9-1F58-4953-A106-46D51704279EQ44676060-C47A318B-8294-40B5-AFC5-F67AD9BA2222Q47848568-402001D1-AB58-4D04-A93B-4448649ACE29Q58128828-E8D57D2A-680E-44B7-B582-26FD5664C36F
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Psychostimulant dependence in a community sample.
@ast
Psychostimulant dependence in a community sample.
@en
Psychostimulant dependence in a community sample.
@nl
type
label
Psychostimulant dependence in a community sample.
@ast
Psychostimulant dependence in a community sample.
@en
Psychostimulant dependence in a community sample.
@nl
prefLabel
Psychostimulant dependence in a community sample.
@ast
Psychostimulant dependence in a community sample.
@en
Psychostimulant dependence in a community sample.
@nl
P2860
P356
P1476
Psychostimulant dependence in a community sample
@en
P2093
William E Schlenger
P2860
P304
P356
10.1081/JA-120017246
P50
P577
2003-01-01T00:00:00Z